<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006267</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068210</org_study_id>
    <secondary_id>GOG-0186B</secondary_id>
    <nct_id>NCT00006267</nct_id>
  </id_info>
  <brief_title>Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Evaluation Of 9-Nitro-Camptothecin In The Third-Line Treatment Of Recurrent Ovarian Or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients&#xD;
      who have recurrent or metastatic ovarian epithelial or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of nitrocamptothecin in patients with recurrent or&#xD;
           metastatic ovarian epithelial or primary peritoneal cancer.&#xD;
&#xD;
        -  Determine the nature and degree of toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral nitrocamptothecin on days 1-5. Treatment continues every 7&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 2 weeks, then every 3 months for 2 years, and then every 6 months&#xD;
      for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 22&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Never activated.&#xD;
  </why_stopped>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rubitecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or metastatic ovarian epithelial or primary&#xD;
             peritoneal cancer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Ascites and pleural effusions are not considered measurable&#xD;
&#xD;
               -  Sonography allowed if bidimensionally measurable&#xD;
&#xD;
          -  Must not be eligible for higher priority GOG protocol&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  GOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and alkaline phosphatase no greater than 3 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent invasive malignancy in the past 5 years except&#xD;
             nonmelanoma skin cancer&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least but no more than 2 prior chemotherapy regimens containing carboplatin,&#xD;
             cisplatin, or another organoplatinum compound combined with paclitaxel&#xD;
&#xD;
          -  Second line therapy may include any agents except topoisomerase I inhibitors (i.e.,&#xD;
             topotecan)&#xD;
&#xD;
          -  No prior nitrocamptothecin or topoisomerase I inhibitors&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior cancer therapy that contraindicates this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward C. Grendys, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <verification_date>May 2004</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 8, 2013</last_update_submitted>
  <last_update_submitted_qc>July 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubitecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

